Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications

Introduction: Poor blood-pressure control and treatment resistance contribute to cardiovascular and kidney complications. Excess aldosterone offers a therapeutic target. Objective: This narrative review evaluates the pharmacological profile, clinical efficacy, safety, and regulatory development of baxdrostat, an oral aldosterone synthase inhibitor designed to preserve cortisol production. Key findings: In BaxHTN, a phase 3 trial in uncontrolled or resistant hypertension, the placebo-adjusted decrease in seated systolic blood pressure at week 12 was 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg; Bax24, a phase 3 ambulatory blood-pressure trial in resistant hypertension, recorded a 14.0 mmHg placebo-adjusted decrease in 24-hour ambulatory systolic pressure with 2 mg. FigHTN, a phase 2 trial in chronic kidney disease, identified a preliminary albuminuria signal, but cardiorenal outcome studies have not yet been completed. The main recognised risks are hyperkalaemia and hyponatraemia, particularly when kidney function is impaired. The United States prescribing information states that safety and effectiveness of initiation at an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2 have not been established, and serum potassium, sodium, and eGFR require surveillance during initiation and dose adjustment. The United States Food and Drug Administration approved baxdrostat (Baxfendy) on May 15, 2026, as an add-on treatment for adults whose hypertension remains inadequately controlled. Concomitant use with a mineralocorticoid receptor antagonist has not been evaluated and should not presently be recommended. Conclusion: Comparative and long-term outcome evidence is still required, while full efficacy and safety results of the completed phase 3 BaxAsia trial in Asian populations are awaited.

Authors

Institutions

Publication Details

Journal
Eurasian Journal of Medicine and Oncology
Published
2026-11-16
DOI
https://doi.org/10.36922/ejmo026310392
Primary Topic
Hormonal Regulation and Hypertension
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications

Erdiansyah Zulyadaini, Witri Pratiwi, Antonia Anna Lukito, Bagus Andi Pramono et al.
3 links
Eurasian Journal of Medicine and Oncology
Hormonal Regulation and Hypertension
article

Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications

Erdiansyah Zulyadaini, Witri Pratiwi, Antonia Anna Lukito, Bagus Andi Pramono, Tuko Srimulyo, Yogi Puji Rachmawan, Wella Karolina, Meity Ardiana
article en

Abstract

Introduction: Poor blood-pressure control and treatment resistance contribute to cardiovascular and kidney complications. Excess aldosterone offers a therapeutic target. Objective: This narrative review evaluates the pharmacological profile, clinical efficacy, safety, and regulatory development of baxdrostat, an oral aldosterone synthase inhibitor designed to preserve cortisol production. Key findings: In BaxHTN, a phase 3 trial in uncontrolled or resistant hypertension, the placebo-adjusted decrease in seated systolic blood pressure at week 12 was 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg; Bax24, a phase 3 ambulatory blood-pressure trial in resistant hypertension, recorded a 14.0 mmHg placebo-adjusted decrease in 24-hour ambulatory systolic pressure with 2 mg. FigHTN, a phase 2 trial in chronic kidney disease, identified a preliminary albuminuria signal, but cardiorenal outcome studies have not yet been completed. The main recognised risks are hyperkalaemia and hyponatraemia, particularly when kidney function is impaired. The United States prescribing information states that safety and effectiveness of initiation at an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2 have not been established, and serum potassium, sodium, and eGFR require surveillance during initiation and dose adjustment. The United States Food and Drug Administration approved baxdrostat (Baxfendy) on May 15, 2026, as an add-on treatment for adults whose hypertension remains inadequately controlled. Concomitant use with a mineralocorticoid receptor antagonist has not been evaluated and should not presently be recommended. Conclusion: Comparative and long-term outcome evidence is still required, while full efficacy and safety results of the completed phase 3 BaxAsia trial in Asian populations are awaited.

Eurasian Journal of Medicine and OncologyVol. 0(0)
Pelita Harapan University (ID), University of Brawijaya (ID), Universitas Airlangga (ID), Universitas Swadaya Gunung Jati (ID), RSUD Prof. Dr. Saiful Anwar Malang (ID)
Good health and well-being
Hormonal Regulation and Hypertension
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon